

DAFTAR PUSTAKA

- Alomar, M.J., 2014. *Factors Affecting The Development of Adverse Drug Reactions (Review Article)*. Saudi Pharmaceutical Journal 22, 83–94. <https://doi.org/10.1016/j.jsps.2013.02.003>.
- Anonim. (2006a). *Adverse Drug Events, Adverse Drug Reactions and Medication Errors*. VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel.
- Anonim. (2006b). *Pharmaceutical Care Untuk Pasien Penyakit Arthritis Rematik*. <https://farmalkes.kemkes.go.id/2013/02/pharmaceutical-care-untuk-pasien-penyakit-arthritis-rematik/>
- Anonim. (2017). *Tool Summary Sheet: Safety Definitions for Clinical Research*. <https://www.hhs.gov/guidance/sites/default/files/hhs-guidance-documents/2008112345-yi-safety-definition-clinicalrsrch.pdf>
- BNF, 2020. *British National Formulary*, 80th ed., Lamberth High Street, London: BMJ Group and RPS Publishing.
- Buys, L. M., & Wiedenfeld, S. A. (2020). Osteoarthritis. In *Pharmacotherapy A Pathophysiologic Approach* (11th ed.). Mc Graw-Hill.
- Cooper, C., Chapurlat, R., Al-Daghri, N., Herrero-Beaumont, G., Bruyère, O., Rannou, F., Roth, R., Uebelhart, D., & Reginster, J. Y. (2019). Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say? In *Drugs and Aging* (Vol. 36, Issue 1, pp. 15–24). Springer International Publishing. <https://doi.org/10.1007/s40266-019-00660-1>
- Couto, A., Troullos, E., Moon, J., Paredes-Diaz, A., & An, R. (2018). Analgesic Efficacy and Safety of Non-Prescription Doses of Naproxen Sodium in the Management of Moderate Osteoarthritis of the Knee or Hip. *Current Medical Research and Opinion*, 34(10), 1747–1753. <https://doi.org/10.1080/03007995.2018.1437029>
- Essex, M. N., Bhadra, P., & Sands, G. H. (2012). Efficacy and Tolerability of Celecoxib versus Naproxen in Patients with Osteoarthritis of the Knee: a Randomized, Double-blind, Double-dummy Trial. In *The Journal of International Medical Research* (Vol. 40).
- Essex, M. N., O'connell And, M., & Bhadra Brown, P. (2012). Response to Nonsteroidal Anti-inflammatory Drugs in African Americans with Osteoarthritis of the Knee a. In *The Journal of International Medical Research* (Vol. 40).
- Essex, M. N., O'connell, M. A., Behar, R., & Bao, W. (2016). *Efficacy and safety of nonsteroidal anti-inflammatory drugs in Asian patients with knee osteoarthritis: summary of a randomized, placebo-controlled study*.

- Farcas, A., & Bojita, M. (2009). Adverse Drug Reactions in Clinical Practice: a Causality Assessment of a Case of Drug-Induced Pancreatitis. *J Gastrointestin Liver Dis*, 18(3), 353–358.
- Felson, D. T. (2008). Osteoarthritis. In *Harrison's Principle of Internal Medicine* (17th ed., pp. 2158–2165). McGraw-Hill Companies Inc.
- Garg, Y., Singh, J., & Kumar Arun. (2017). Comparison of Clinical Effectiveness and Safety of Newer Nonsteroidal Anti-inflammatory Drugs in Patients of Osteoarthritis of Knee Joint: A Randomized, Prospective, Open-label Parallel-group Study. *Indian J Pharmacol*, 49(5), 383–389.
- Goulet, J. L., Buta, E., Brennan, M., Heapy, A., & Fraenkel, L. (2018). Discontinuing a Non-Steroidal Anti-Inflammatory Drug (NSAID) in Patients With Knee Osteoarthritis: Design and Protocol of a Placebo-Controlled, Noninferiority, Randomized Withdrawal Trial. *Contemporary Clinical Trials*, 65, 1–7. <https://doi.org/10.1016/j.cct.2017.11.020>
- Hawker, G. A. (2019). Osteoarthritis is a Serious Disease. *Clinical and Experimental Rheumatology*, 37(120), S-3-S-6.
- IRA. (2014a). *Diagnosis dan Penatalaksanaan Osteoarthritis*. https://reumatologi.or.id/wp-content/uploads/2020/10/Rekomendasi_Osteoarthritis_2014.pdf
- IRA. (2014b). *Penggunaan Obat Anti Inflamasi Non Steroid*. https://reumatologi.or.id/wp-content/uploads/2020/10/Rekomendasi_OAINS_2014.pdf
- Johnson, V. L., & Hunter, D. J. (2014). The Epidemiology of Osteoarthritis. *Best Practice and Research: Clinical Rheumatology*, 28(1), 5–15. <https://doi.org/10.1016/j.berh.2014.01.004>
- Kementerian Kesehatan RI. (2018). Hasil Utama RISKESDAS 2018. <https://www.litbang.kemkes.go.id/hasil-utama-risikesdas-2018/>.
- Kementerian Kesehatan RI. (2019). *Formularium Nasional*. Departemen Kesehatan Republik Indonesia. Jakarta.
- Kloppenburg, M., & Berenbaum, F. (2020). Osteoarthritis Year in Review 2019 : Epidemiology and Therapy. *Osteoarthritis and Cartilage*, 28(3), 242–248.
- Lee, M., Yoo, J., Kim, J. G., Kyung, H. S., Bin, S. il, Kang, S. B., Choi, C. H., Moon, Y. W., Kim, Y. M., Han, S. B., In, Y., Choi, C. H., Kim, J., Lee, B. K., & Cho, S. (2017). A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis. *CiOS Clinics in*

Orthopedic Surgery, 9(4), 439–457.
<https://doi.org/10.4055/cios.2017.9.4.439>

Lespasio, M. J., Piuizzi, N. S., Husni, M. E., Muschler, G. F., Guarino, A., & Mont, M. A. (2017). Knee Osteoarthritis: A Primer. *The Permanente Journal*, 21. <https://doi.org/10.7812/TPP/16-183>

Musumeci, G., Aiello, F. C., Szychlinska, M. A., di Rosa, M., Castrogiovanni, P., & Mobasheri, A. (2015). Osteoarthritis in The XXIst Century: Risk Factors and Behaviours That Influence Disease Onset and Progression. *International Journal of Molecular Sciences*, 16(3), 6093–6112. <https://doi.org/10.3390/ijms16036093>

Nayaka, S. R., Mamatha, K. R., & Raju, K. V. P. K. (2014). A Comparative Study to Assess the Efficacy and Tolerability of Lornoxicam and Diclofenac in Patients with Osteoarthritis of Knee in a Tertiary Care Hospital. Available Online *Www.Jocpr.Com Journal of Chemical and Pharmaceutical Research*, 6(3), 1306–1311. www.jocpr.com

Nursalim, A. J., & Ndraha, S. (2013). *Clinical Efficacy and Side Effects of Nabumeton Compared to Meloxicam in Osteoarthritis Pain*.

Osteoarthritis Action Alliance. (2020). *A National Public Health Agenda for Osteoarthritis* 2020. https://oaaction.unc.edu/wp-content/uploads/sites/623/2020/05/OA-Agenda-Final_04302020.pdf

Pareek, A., & Chandurkar, N. (2013). Comparison of Gastrointestinal Safety and Tolerability of Aceclofenac with Diclofenac: A Multicenter, Randomized, Double-Blind Study in Patients with Knee Osteoarthritis. *Current Medical Research and Opinion*, 29(7), 849–859. <https://doi.org/10.1185/03007995.2013.795139>

Pareek, A., Chandurkar, N., Gupta, A., Sirsikar, A., Dalal, B., Jesalpura, B., Mehrotra, A., & Mukherjee, A. (2011). Efficacy and Safety of Aceclofenac-CR and Aceclofenac in the Treatment of Knee Osteoarthritis: A 6-Week, Comparative, Randomized, Multicentric, Double-Blind Study. *Journal of Pain*, 12(5), 546–553. <https://doi.org/10.1016/j.jpain.2010.10.013>

Rogoveanu, Streba, C., Vere, C., Petrescu, L., & Traistaru, R. (2015). Superior Digestive Tract Side Effects After Prolonged Treatment with NSAIDs in Patients with Osteoarthritis. In *Journal of Medicine and Life* (Vol. 8).

Shin, J. Y., Chang, M. J., Kim, M. K., Kang, S. B., Kim, K. il, Park, H. G., Lee, S., Kim, S. H., Han, S. B., Lee, H. J., Moon, Y. W., & Yoo, J. D. (2020). Efficacy and Safety of Short-Term use of a Pelubiprofen CR and Aceclofenac in Patients with Symptomatic Knee Osteoarthritis: A Double-blinded, randomized, multicenter, active drug comparative, parallel-group, phase IV, non-inferiority clinical trial. *PLoS ONE*, 15(9 September). <https://doi.org/10.1371/journal.pone.0238024>

- Soeroso, J., Harry Isbagio, Handono Kalim, Rawan Broto, & Riardi Pramudiyo. (2014). Osteoarthritis. In *Buku Ajar Ilmu Penyakit Dalam* (6th ed., pp. 3197–3209). Fakultas Kedokteran Universitas Indonesia.
- Sukandar, E. Y., Andrajati, R., Sigit, J. I., Adnyana, I. K., Setiadi, A. A. P., & Kusnandar. (2013). Osteoarthritis. In *ISO Farmakoterapi* (pp. 629–644). ISFI Penerbitan.
- Wells, B. G., DiPiro, J. T., Schwinghammer, T. L., & DiPiro, C. v. (2015). Osteoarthritis. In *Pharmacotherapy Handbook* (Ninth Edition, pp. 9–15). Mc Graw-Hill.
- Wijaya, S. (2018). Osteoarthritis Lutut. *CDK-265*, 45(6), 424–429.
- Wittenauer, R., Smith, L., & Aden, K. (2013). *Osteoarthritis*. https://www.who.int/medicines/areas/priority_medicines/BP6_12Osteo.pdf
- Wulandari, N., Andrajati, R., & Supardi, S. (2016). *Faktor Risiko Umur Lansia terhadap Kejadian Reaksi Obat yang Tidak Dikehendaki pada Pasien Hipertensi, Diabetes, Dislipidemia di Tiga Puskesmas di Kota Depok*. 6(1), 60–67.
- Zamani, O., Böttcher, E., Rieger, J. D., Mitterhuber, J., Hawel, R., Stallinger, S., & Eller, N. (2014). Comparison of Safety, Efficacy and Tolerability of Dexibuprofen and Ibuprofen in the Treatment of Osteoarthritis of the Hip or Knee. *Wiener Klinische Wochenschrift*, 126(11–12), 368–375. <https://doi.org/10.1007/s00508-014-0544-2>